Oxidized phospholipids and isoprostanes in atherosclerosis : Current Opinion in Lipidology

Secondary Logo

Journal Logo

Advanced Search
Atherosclerosis: Cell Biology And Lipoproteins

Oxidized phospholipids and isoprostanes in atherosclerosis

Witztum, Joseph L.a; Berliner, Judith A.b

Author Information

aDepartment of Medicine, University of California San Diego, and bDepartment of Pathology, Division of Cardiology, University of California, Los Angeles, USA

Abbreviations;

apo: apolipoprotein;

GCMS: gas chromatography–mass spectrometry;

LCAT: lecithin:cholesterol acyltransferase;

MM‐LDL: minimally modified LDL;

OxLDL: oxidized LDL;

OxPAPC: oxidized 1‐palmitoyl‐2‐arachidonyl‐sn‐glycero‐3‐phosphocholine;

OxPL: oxidized phopholipids;

PAF: platelet‐activating factor;

PAF‐AH: PAF‐acetylhydrolase;

PGE2: prostaglandin E2;

PGF2: prostaglandin F2;

PLA2: phospholipase A2;

SMC: smooth muscle cell;

Current Opinion in Lipidology 9(5):p 441-448, October 1998.

Abstract

Lipid oxidation has been shown to be a prominent feature of atherosclerosis. The presence of isoprostanes and other lipid oxidation products has been clearly demonstrated in lesions. Furthermore, antibodies to oxidized phopholipids have been identified in animal and human models. Recent evidence suggests that oxidized phospholipids may activate all vascular cell types. The identification and isolation of particular oxidative products has provided some important information about the receptors for these active lipids. Curr Opin Lipidol 9:441–448. © 1998 Lippincott Williams & Wilkins

© 1998 Lippincott Williams & Wilkins, Inc.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid